Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Increased by Fred Alger Management LLC

Fred Alger Management LLC boosted its position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 1,515.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,553 shares of the company's stock after buying an additional 166,560 shares during the quarter. Fred Alger Management LLC owned 0.16% of Centessa Pharmaceuticals worth $2,839,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CNTA. First Light Asset Management LLC boosted its holdings in Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock valued at $35,518,000 after purchasing an additional 850,000 shares in the last quarter. FMR LLC boosted its stake in shares of Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company's stock valued at $46,635,000 after buying an additional 129,300 shares during the last quarter. Driehaus Capital Management LLC grew its position in shares of Centessa Pharmaceuticals by 89.5% during the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock worth $18,891,000 after buying an additional 987,997 shares in the last quarter. Finally, Farallon Capital Management LLC increased its stake in shares of Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock worth $18,024,000 after buying an additional 1,625,000 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock traded down $0.96 on Monday, reaching $16.95. 519,789 shares of the company were exchanged, compared to its average volume of 418,025. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of -11.52 and a beta of 1.47. Centessa Pharmaceuticals plc has a 1-year low of $6.15 and a 1-year high of $18.74. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company's 50-day moving average is $16.22 and its two-hundred day moving average is $12.72.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on CNTA shares. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective on the stock. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Oppenheimer restated an "outperform" rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Guggenheim boosted their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, November 15th. Finally, BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research note on Monday, September 16th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $25.83.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now directly owns 183,266 shares of the company's stock, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Saurabh Saha sold 1,671 shares of the firm's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04. Following the transaction, the chief executive officer now owns 575,661 shares in the company, valued at $10,500,056.64. This represents a 0.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 375,128 shares of company stock valued at $6,148,522 in the last ninety days. Company insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.